hero section gradient
15 handpicked stocks

Post-IRA Energy Shift

A carefully selected group of energy companies positioned to benefit from potential U.S. policy changes affecting renewables. These stocks were handpicked by our analysts to give you exposure to nuclear, natural gas, and domestic manufacturers that could gain market share if Chinese-component taxes are implemented.

Author avatar

Han Tan | Market Analyst

Published on June 30

Your Basket's Financial Footprint

Interpretation data for the 'Post-IRA Energy Shift' basket including total market cap and breakdown.

Key Takeaways for Investors:
  • Large-cap dominance tends to imply lower volatility and steadier returns, tracking broad-market behaviour.
  • Best positioned as a core holding within a diversified portfolio, not a speculative high-growth bet.
  • Expect steady long-term value rather than explosive short-term gains; significant outperformance is less likely.
Total Market Cap
  • FSLR: $24.33B

  • EQT: $34.77B

  • CCJ: $36.04B

  • Other

About This Group of Stocks

1

Our Expert Thinking

This collection focuses on companies that could benefit if proposed legislation taxes Chinese-made components in wind and solar projects. The policy shift could redirect investment toward nuclear power, natural gas, and U.S.-based equipment manufacturers as renewable development potentially slows.

2

What You Need to Know

These stocks span several energy sectors: nuclear operators and uranium suppliers, natural gas producers and infrastructure companies, and U.S.-based solar equipment manufacturers with domestic supply chains. They're positioned as potential beneficiaries of a changing energy landscape.

3

Why These Stocks

Our analysts selected these companies based on their strategic positioning to gain market share if U.S. energy policy shifts away from Chinese-dependent renewables. Each company offers exposure to alternative energy sources or domestic manufacturing capabilities that could see increased demand.

Why You'll Want to Watch These Stocks

📊

Policy Pivot Potential

These stocks are positioned to benefit from a significant shift in U.S. energy policy that could reshape the renewable energy landscape, creating opportunities for alert investors.

🔋

Beyond Wind and Solar

While everyone focuses on traditional renewables, these companies represent alternative energy solutions that could surge if anti-Chinese component legislation passes.

🏭

Made in America Advantage

Several companies in this group feature domestic manufacturing and supply chains that would gain a competitive edge if Chinese components face new tariffs.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions